Conference Highlights
More representation from big pharma than ever before. Hear new data and strategic perspectives from Merck, Genzyme, and GlaxoSmithKline, including three presentations from Glaxo on a peptide project and their assessments of both the oligo and peptide landscape.
A robust field of keynote presentations, including an update on the clinical development of mipomersen from Genzyme and a look back on 2011 as a pivotal year for oligonucleotide therapeutics by Arthur Levin of Santaris A/S.
Pre-conference tutorials to increase your knowledge:
- Technical and Regulatory Aspects of Peptide Specifications and Characterization: From Preclinical through to Market Application
- Strategies and Approaches for in vivo Delivery of Oligonucleotides
Brand new regulatory session on preclinical safety assessment, including an update from the Oligo Safety Working Group and – new this year – 2 talks from the JPMA.
Unpublished new data on the Combinatorial Development of Biomaterials and Synthetic siRNA Delivery Systems by Dan Anderson, Associate Professor of Chemical Engineering at Massachusetts Institute of Technology.
Two timely presentations on peptide-based vaccines:
- (CASE STUDY) Design Considerations for DPX-Survivac, a Multi-Cancer Peptide-Based Vaccine
- (UNPUBLISHED DATA) Speeding up Peptide-Based Vaccine Research with VesiVax® Conjugatable Adjuvant Lipid Vesicles (CALV)
An insightful talk on Pharmaceutical Protein and Peptide Engineering by Jesper Lau, Vice President of Diabetes Protein and Peptide Chemistry at Novo Nordisk, Denmark
Glaxo’s CMC perspective on industrialising a therapeutic oligo portfolio presented by Mike Webb, Head of API Chemistry and Analysis at GSK UK
|